Thalassemia and hypercoagulability

Area of Science:

• Hematology
• Vascular Medicine
• Pharmacology

Background:

• Beta-thalassemia management has improved, but thrombotic events remain a major complication.
• A hypercoagulable state is evident, especially in non-transfusion-dependent beta-thalassemia, driven by factors like oxidative stress and endothelial activation.
• Splenectomy and increased survival complications like atrial fibrillation add to thrombotic risk.

Purpose of the Study:

• To review the complex thrombotic risk factors in beta-thalassemia.
• To discuss the potential role of emerging therapies, such as luspatercept, in managing thrombosis.
• To highlight the need for specialized guidelines for thrombosis prevention and management in beta-thalassemia patients.

Main Methods:

• Literature review of studies on thrombosis in beta-thalassemia.
• Analysis of disease-specific contributors to hypercoagulability.
• Evaluation of current management strategies and emerging therapeutic options.

Main Results:

• Disease-specific factors (ROS, pathological erythroid cells, microparticles, free heme, endothelial activation) contribute to hypercoagulability.
• Splenectomy and atrial fibrillation are significant risk factors.
• Luspatercept shows potential but requires further investigation for its role in modifying thrombotic risk.

Conclusions:

• Current thrombosis management in beta-thalassemia relies on general population guidelines, which may be insufficient.
• Robust data is needed to develop dedicated guidelines tailored to the unique pathophysiology and risk factors of beta-thalassemia.
• Further research on novel agents like luspatercept is crucial for optimizing patient care.